

DEXTROSE AND SODIUM CHLORIDE- dextrose monohydrate and sodium chloride injection, solution

Fresenius Kabi USA, LLC

5% Dextrose and 0.9% Sodium Chloride Injection, USP

free flex[®]

Rx only


DESCRIPTION

Dextrose and Sodium Chloride Injection, USP solutions are sterile and nonpyrogenic. They are large volume parenteral solutions containing 5 grams per 100 mL of Dextrose monohydrate and 0.9 grams per 100 mL of Sodium Chloride in water for injection intended for intravenous administration. Electrolytes per 1000 mL: sodium (Na^+), 154 mEq; chloride (Cl^-) 154 mEq. The osmolarity is 560 mOsmol/L (calc.), which is hypertonic. The caloric value is 170 kcal/L. The pH is 4.3 (3.5 to 6.5).

The solutions contain no bacteriostat, antimicrobial agent or added buffer and each is intended only as a single-dose injection. When smaller doses are required the unused portion should be discarded.

The solutions are parenteral fluid, nutrient and electrolyte replenishers.

Dextrose, USP is chemically designated D-glucose monohydrate ($\text{C}_6\text{H}_{12}\text{O}_6 \cdot \text{H}_2\text{O}$), a hexose sugar freely soluble in water. It has the following structural formula:



Sodium Chloride, USP is chemically designated NaCl, a white crystalline powder freely soluble in water.

Water for Injection, USP is chemically designated H₂O.

The flexible container is fabricated from a specially formulated non-plasticized, film containing polypropylene and thermoplastic elastomers (**freeflex[®]** bag). The amount of water that can permeate from the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the flexible container can leach out certain of the container's chemical components in very small amounts within the expiration period. The suitability of the container material has been confirmed by tests in animals according to USP biological tests for plastic containers.

CLINICAL PHARMACOLOGY

When administered intravenously, these solutions provide a source of water, carbohydrate and electrolytes.

Solutions which provide combinations of hypotonic or isotonic concentrations of dextrose and of sodium chloride are suitable for parenteral maintenance or replacement of water and electrolyte requirements with minimal carbohydrate calories.

Solutions containing carbohydrate in the form of dextrose restore blood glucose levels and provide calories. Carbohydrate in the form of dextrose may aid in minimizing liver glycogen depletion and exerts a protein-sparing action. Dextrose injected parenterally undergoes oxidation to carbon dioxide and water.

Sodium chloride in water dissociates to provide sodium (Na^+) and chloride (Cl^-) ions. Sodium (Na^+) is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Chloride (Cl^-) has an integral role in buffering action when oxygen and carbon dioxide exchange occurs in the red blood cells. The distribution and excretion of sodium (Na^+) and chloride (Cl^-) are largely under the control of the kidney which maintains a balance between intake and output.

Water is an essential constituent of all body tissues and accounts for approximately 70% of total body weight. Average normal adult daily requirements range from two to three liters (1.0 to 1.5 liters each for insensible water loss by perspiration and urine production). Water balance is maintained by various regulatory mechanisms. Water distribution depends primarily on the concentration of electrolytes in the body compartments and sodium (Na^+) plays a major role in maintaining physiologic equilibrium.

INDICATIONS AND USAGE

Intravenous solutions containing dextrose and sodium chloride are indicated for parenteral replenishment of fluid, minimal carbohydrate calories, and sodium chloride as required by the clinical condition of the patient.

CONTRAINDICATIONS

None known.

WARNINGS

Solutions containing sodium ions should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency and in clinical states in which there exists edema with sodium retention.

Excessive administration of potassium-free solutions may result in significant hypokalemia. In patients with diminished renal function, administration of solutions containing sodium ions may result in sodium retention.

The intravenous administration of these solutions can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema.

The risk of dilutional states is inversely proportional to the electrolyte concentrations of administered parenteral solutions. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentrations of such solutions.

PRECAUTIONS

Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation.

Solutions containing dextrose should be used with caution in patients with known subclinical or overt diabetes mellitus.

Caution must be exercised in the administration of parenteral fluids, especially those containing sodium ions to patients receiving corticosteroids or corticotropin.

Do not administer unless solution is clear and container is undamaged. Discard unused portion.

Pregnancy Category C. Animal reproduction studies have not been conducted with dextrose or sodium chloride. It is also not known whether dextrose or sodium chloride can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Dextrose or sodium chloride should be given to a pregnant woman only if clearly needed.

Pediatric Use. The safety and effectiveness in the pediatric population are based on the similarity of the clinical conditions of the pediatric and adult populations. In neonates or very small infants, the volume of fluid may affect fluid and electrolyte balance.

Frequent monitoring of serum glucose concentrations is required when dextrose is prescribed to pediatric patients, particularly neonates and low birth weight infants.

In very low birth weight infants, excessive or rapid administration of dextrose injection may result in increased serum osmolality and possible intracerebral hemorrhage.

Geriatric Use. An evaluation of current literature revealed no clinical experience identifying differences in response between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Sodium ions are known to be substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

ADVERSE REACTIONS

Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia.

If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.

OVERDOSAGE

In the event of overhydration or solute overload, re-evaluate the patient and institute appropriate corrective measures. See **WARNINGS**, **PRECAUTIONS**, and **ADVERSE REACTIONS**.

DOSAGE AND ADMINISTRATION

The dose is dependent upon the age, weight and clinical condition of the patient.

As reported in the literature, the dosage and constant infusion rate of intravenous dextrose must be selected with caution in pediatric patients, particularly neonates and low birth weight infants, because of the increased risk of hyperglycemia/hypoglycemia.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. See **PRECAUTIONS**.

Drug Interactions

Additives may be incompatible. Consult with pharmacist, if available. When introducing additives, use aseptic technique, mix thoroughly and do not store.

INSTRUCTIONS FOR USE:

Check flexible container solution composition, lot number, and expiry date.

Do not remove solution container from its overwrap until immediately before use. Use sterile equipment and aseptic technique.

To Open

1. Turn solution container over so that the text is face down. Using the pre-cut corner tabs, peel open the overwrap and remove solution container.
2. Check the solution container for leaks by squeezing firmly. If leaks are found, or if the seal is not intact, discard the solution.
3. Do not use if the solution is cloudy or a precipitate is present.

To Add Medication

1. Identify WHITE Additive Port with arrow pointing toward container.
2. Immediately before injecting additives, break off WHITE Additive Port Cap with the arrow pointing toward container.
3. Hold base of WHITE Additive Port horizontally.
4. Insert needle horizontally through the center of WHITE Additive Port's septum and inject additives.
5. Mix container contents thoroughly.

Preparation for Administration

1. Immediately before inserting the infusion set, break off BLUE Infusion Port Cap with the arrow pointing away from container.
2. Use a non-vented infusion set or close the air-inlet on a vented set.
3. Close the roller clamp of the infusion set.
4. Hold the base of BLUE Infusion Port.
5. Insert spike through BLUE Infusion Port by rotating wrist slightly until the spike is inserted.
NOTE: See full directions accompanying administration set.

WARNING: Do not use flexible container in series connections.

HOW SUPPLIED

5% Dextrose and 0.9% Sodium Chloride Injection, USP is supplied in single-dose flexible plastic containers in 500 mL and 1000 mL sizes as follows:

Product Name	Size	Number per Carton	NDC	Product Code
5% Dextrose and 0.9% Sodium Chloride Injection, USP	500 mL	20	NDC 63323-870-10	870110
5% Dextrose and 0.9% Sodium Chloride Injection, USP	1000 mL	10	NDC 63323-870-74	870174

The container closure is not made with natural rubber latex. Non-PVC, Non-DEHP, Sterile.

Protect from freezing. Store at **20° to 25°C (68° to 77°F)**. [See USP Controlled Room Temperature.]

Manufactured for:



Lake Zurich, Illinois 60047

Made in Germany

451685

www.fresenius-kabi.com/us

Issued: September 2020

PACKAGE LABEL - PRINCIPAL DISPLAY – Dextrose and Sodium Chloride 500 mL Bag Label

NDC 63323-870-10

free flex[®]


500 mL

5% Dextrose and 0.9% Sodium Chloride Injection, USP

For intravenous use. Rx only



NDC 63323-870-10



500 mL

5% Dextrose and 0.9% Sodium Chloride Injection, USP

100

For intravenous use.

Rx only

Each 100 mL contains: Dextrose, Hydrous 5 g;
Sodium Chloride 900 mg in water for injection.
Electrolytes per 1000 mL: Sodium 154 mEq; Chloride 154 mEq.
560 mOsmol/Liter (Calc). pH 4.3 (3.5 to 6.5)

200

Additives may be incompatible. Consult with pharmacist, if available. When introducing additives, use aseptic technique, mix thoroughly and do not store. Single-Dose Container.

Usual dosage: See package insert.
The overwrap is a moisture barrier.

Use immediately once removed from overwrap.

300

STORE AT: 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from freezing.

The container closure is not made with natural rubber latex. Non-PVC, Non-DEHP, Sterile.



(01)00363323870102

400

Mfd. for:



Lake Zurich, IL 60047


Made in Germany

www.fresenius-kabi.com/us


403694

LOT

EXP



0744451/00 US



PACKAGE LABEL - PRINCIPAL DISPLAY – Dextrose and Sodium Chloride 1000 mL Bag Label





NDC 63323-870-74

free flex[®]

1000 mL

5% Dextrose and 0.9% Sodium Chloride Injection, USP

For intravenous use. Rx only

100		NDC 63323-870-74	
	free flex [®]		1000 mL
200	5% Dextrose and 0.9% Sodium Chloride Injection, USP		
300	For intravenous use.		Rx only
	Each 100 mL contains: Dextrose, Hydrated 5 g; Sodium Chloride 900 mg in water for injection. Electrolytes per 1000 mL: Sodium 154 mEq; Chloride 154 mEq. 560 mOsmol/Liter (Calc). pH 4.3 (3.5 to 6.5)		
400	Additives may be incompatible. Consult with pharmacist, if available. When introducing additives, use aseptic technique, mix thoroughly and do not store. Single-Dose Container.		
500	Usual dosage: See package insert. The overwrap is a moisture barrier. Use immediately once removed from overwrap.		
	STORE AT: 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from freezing.		
600	The container closure is not made with natural rubber latex. Non-PVC, Non-DEHP, Sterile.		
	 (01)00363323870744		
700			
800	Mfd. for:  Lake Zurich, IL 60047 Made in Germany www.fresenius-kabi.com/us 403695	LOT	
		EXP	
900		0744461/00 US	

DEXTROSE AND SODIUM CHLORIDE

dextrose monohydrate and sodium chloride injection, solution

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:63323-870
Route of Administration	INTRAVENOUS		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
DEXTROSE MONOHYDRATE (UNII: LX22YL083G) (ANHYDROUS DEXTROSE - UNII:5SL0G7R0OK)	DEXTROSE MONOHYDRATE	5 g in 100 mL
SODIUM CHLORIDE (UNII: 451W47IQ8X) (SODIUM CATION - UNII:LYR4M0NH37, CHLORIDE ION - UNII:Q32ZN48698)	SODIUM CHLORIDE	0.9 g in 100 mL

Inactive Ingredients

Ingredient Name	Strength
WATER (UNII: 059QF0K00R)	

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:63323-870-10	20 in 1 CASE	10/26/2020	
1		500 mL in 1 BAG; Type 0: Not a Combination Product		
2	NDC:63323-870-74	10 in 1 CASE	10/26/2020	
2		1000 mL in 1 BAG; Type 0: Not a Combination Product		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA211211	10/26/2020	

Labeler - Fresenius Kabi USA, LLC (608775388)

Establishment

Name	Address	ID/FEI	Business Operations
Fresenius Kabi Deutschland GmbH		506719546	ANALYSIS(63323-870) , MANUFACTURE(63323-870)

Revised: 1/2021

Fresenius Kabi USA, LLC